Biased GLP-1R agonism has emerged as a promising therapeutic strategy for T2D on the basis of preclinical evaluations [8], [9], [11] and the recent recognition that some of the beneficial effects of the dual GLP-1R/GIPR agonist tirzepatide may be due to biased agonism at the GLP-1R [14]. This evidence concerns the gene GIPR and type 2 diabetes mellitus.